DruSO-CU

This international project aims to calculate the drug survival of omalizumab in a large multicenter daily practice cohort of patients with CU treated in UCARE centers, and identify determinants of drug survival in this overall international population differentiated by reason of discontinuation.

Contact: H.Rockmann@umcutrecht.nl

Soon it will be October 1st and urticaria day again. And who cares? UCARE! UCARE is a worldwide network of specialized treatment centers (Urticaria Centers of Reference and Excellence)

Read more

This year’s EAACI meeting had a strong focus on urticaria and angioedema, a great forum for urticariologists and a great opportunity for UCAREs to connect.

Read more

We are glad to welcome the newest members to the UCARE family

Read more

Contact us

GA²LEN coordinating Office
Charité Universitätsmedizin Berlin
Luisenstr. 2-5
10117 Berlin, Germany

UCARE office
Laura Schwenner

info(at)ga2len-ucare.com